Astex Pharmaceuticals (ASTX)
Astex Pharmaceuticals Revenue Growth: 28.81%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ASTX Revenue Growth Rankings
| Overall | 83rd percentile | 699 of 4358 |
| Sector | 77th percentile | 102 of 456 in Healthcare |
| Industry | 77th percentile | 4 of 18 in Drug Manufacturers - Major |
ASTX Revenue Growth Range, Past 5 Years
| Minimum | -80.74% | Jun 2007 |
| Maximum | 170.7% | Dec 2007 |
| Average | 32.09% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these ASTX related companies
ASTX News
Astex Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Apr 30, 7:30PM Seeking Alpha
Apr 30, 7:30PM Seeking Alpha
$ASTX filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3acx
about 27 days ago by MarketBrief
about 27 days ago by MarketBrief
Listen to $ASTX Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3aTc
about 27 days ago by earningscast
about 27 days ago by earningscast
Astex Pharmaceuticals to Announce 2012 First Quarter Financial Results on April 30, 2012
Apr 24, 6:00AM GlobeNewswire
Apr 24, 6:00AM GlobeNewswire
Listen to $ASTX Astex Pharmaceuticals Inc at BioCentury & Thomson Reuters Future - live at 09:30 AM, ondemand after - http://stks.co/3Qvl
about 37 days ago by earningscast
about 37 days ago by earningscast
Astex Pharmaceuticals to Present AT26893, a Novel Targeted Approach to the Treatment of HCV at EASL
Apr 13, 6:00AM GlobeNewswire
Apr 13, 6:00AM GlobeNewswire
Astex Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
Apr 13, 5:00AM GlobeNewswire
Apr 13, 5:00AM GlobeNewswire
Astex Pharmaceuticals Announces Subcutaneous SGI-110 Interim Phase 1/2 MDS and AML Data Presentation at AACR
Apr 03, 6:00AM GlobeNewswire
Apr 03, 6:00AM GlobeNewswire
Last week’s IPOs & Transactions > http://stks.co/3Bhz > $ASTX $ATPG $BVTI $JOS $MIK
about 55 days ago by BHSMITH
about 55 days ago by BHSMITH
Astex Pharmaceuticals, Inc. [ASTX] to Ring The NASDAQ Stock Market Opening Bell
Mar 26, 10:59AM GlobeNewswire
Mar 26, 10:59AM GlobeNewswire
Astex Pharmaceuticals Announces March 27th Analyst and Investor Day Agenda
Mar 21, 6:00AM Business Wire
Mar 21, 6:00AM Business Wire
$ASTX really wants some news and something to explode this stock !
about 68 days ago by Crebelman2224
about 68 days ago by Crebelman2224
$ASTX http://stks.co/2s3m Watching for a breakout of this downtrend line
about 74 days ago by jamiemc101
about 74 days ago by jamiemc101
$ASTX looking hard at buying whats coming down the pipes short term?
about 75 days ago by Crebelman2224
about 75 days ago by Crebelman2224
Astex Pharma (ASTX) sNDA for Dacogen Declined by FDA; Did Not Show Statistical Superiority
Mar 07, 6:50AM Street Insider
Mar 07, 6:50AM Street Insider
$CYCC has been assignet patent for Sapacitabine treatment of MDS and a methods of treating proliferative disorder http://stks.co/2hds $ASTX
about 82 days ago by biotech
about 82 days ago by biotech
Astex Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Mar 05, 8:10PM Seeking Alpha
Mar 05, 8:10PM Seeking Alpha
Astex Pharmaceuticals Reports 2011 Fourth Quarter and Year-End Financial Results
Mar 05, 4:00PM Business Wire
Mar 05, 4:00PM Business Wire
Astex Pharmaceuticals to Announce 2011 Fourth Quarter and Year-End Financial Results on March 5, 2012
Feb 28, 6:00AM Business Wire
Feb 28, 6:00AM Business Wire
Astex Pharmaceuticals to Host Annual Analyst and Investor Day on March 27, 2012
Feb 16, 6:00AM Business Wire
Feb 16, 6:00AM Business Wire
Astex (ASTX) Says FDA Committee Won't Support Dacogen Benefit/Risk Profile; Stock to Resume at 2:05pm ET
Feb 09, 2:04PM Street Insider
Feb 09, 2:04PM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ASTX | 1.81 | +0.06 | +3.43% | 168.46M |
| ASTMD | 2.05 | -0.01 | -0.49% | |
| ASTM | 2.05 | -0.01 | -0.49% | 79.46M |
| ASTI | 0.5391 | -0.02 | -3.73% | 22.08M |
| ASTE | 28.39 | -0.11 | -0.39% | 644.74M |
| BBOX | 22.22 | +0.19 | +0.86% | 388.41M |
| BBNK | 15.01 | +0.03 | +0.20% | 227.70M |
| BBL | 53.22 | -0.73 | -1.35% | 56.90B |
| BBH | 46.16 | +0.28 | +0.61% | |
| BBGI | 5.76 | +0.00 | +0.00% | 130.98M |
